Associated Papers
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Li Y et al.
Esmo Open, 2024
Pathways and targeting avenues of BRAF in non-small cell lung cancer.
Imyanitov EN et al.
Expert Opinion on Therapeutic Targets, 2024
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
37483495 (PubMed )
Supplement: Table_4.xlsx › All_melanoma-targeted_subpanel
Ongoing progress in BRAF-mutated non-small cell lung cancer.
Abdayem P et al.
Clinical Advances in Hematology & Oncology : H&o, 2022
Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer.
Ghezelayagh TS et al.
Cancer Research Communications, 2022
36311816 (PubMed )
Supplement: crc-22-0314-s02.xlsx › Table_S6_List_of_mutations
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes.
Di Federico A et al.
Cancers, 2022
35884534 (PubMed )
Supplement: cancers-14-03472-s001.zip › cancers-1806422-supplementary.pdf
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
Riudavets M et al.
Lung Cancer (amsterdam, Netherlands), 2022
Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
Awada G et al.
Current Opinion in Oncology, 2022
Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients.
Peng P et al.
Annals of Translational Medicine, 2021
Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer.
Mendis S et al.
Clinical Colorectal Cancer, 2020
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M et al.
Oncogene, 2018
Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S et al.
Endocrine, 2016
Select a paper to view details